Consortium invests $30m in series-B round for Eyevensys
Boehringer Ingelheim Venture Fund has led a $30m series-B round for France-based Eyevensys, a clinical-stage biotechnology company developing non-viral gene therapies for retinal and other ophthalmic diseases.
More on Expansion
Vesalius, Swisscanto in €19m series-B for OncoDNA
Fresh capital will be used for international growth and software development acceleration
KCP invest £5m in Commhoist
Commhoist is a specialist mobile telecoms logistics provider based in Warrington and founded in 1996
Kinnevik leads $51.6m round for Mathem
Round also saw participation from AMF, which invested $28.9m
TCV leads $500m round for Revolut at $6bn valuation
TCV is currently investing from its TCV X fund, which closed on $3bn and invests $75-150m
Latest News
Vesalius, Swisscanto in €19m series-B for OncoDNA
Fresh capital will be used for international growth and software development acceleration
KCP invest £5m in Commhoist
Commhoist is a specialist mobile telecoms logistics provider based in Warrington and founded in 1996
US pension earmarks $25m for private debt secondaries
Augusta-based MainePERS has invested 3.5% of its portfolio to alternative credit
Main Capital sells TPSC to PE-backed Symplr
Sale ends a six-year holding period for the GP, which bought TPSC via its €40m Main Capital III fund